Moffitt Cancer Center's Genitourinary Oncology Program is a world-class destination for patients with cancers of the urinary tract and male genital organs. We are a high-volume, National Cancer Institute-designated Comprehensive Cancer Center with concentrated programs for even the rarest malignancies, and many of our physicians are fellowship-trained in urologic sub-specialties. As a result, we are a trusted partner of physicians across the nation who need to refer their patients to an advanced program for genitourinary cancer diagnosis or treatment.
Our Genitourinary Oncology Program can accommodate referrals for patients who have been diagnos
ed with or require diagnostic testing for any of the following cancers:
- Adrenal cancer
- Bladder cancer
- Kidney cancer
- Penile cancers
- Prostate cancer
- Renal cell cancer
- Testicular cancer
- Urethral, urachal, ureteral or urothelial cancer
- Other rare urologic conditions, such as Wilms’ kidney tumor and Von Hippel Lindau disease
Moffitt's advanced Genitourinary Oncology Program offers a comprehensive range of services, from chemotherapy, radiation therapy and surgery to nuclear medicine, pathology and supportive care. Due to a direct line of communication between each of these subspecialties, we are able to provide patients with comprehensive treatment plans without the frustrations of being referred from specialist to specialist. We specialize in complex treatments, such as robotic surgeries and organ preserving surgeries; our team performs a substantial number of these procedures each year. Furthermore, through our robust research programs, we offer patients access to emerging therapies, such as immunotherapy, ablation and focal therapy. And, our tumor board meets weekly to review each patient’s case, ensuring automatic and consistent monitoring of treatment results. This approach also contributes to survival outcomes that are routinely better than national averages and a higher quality of life for each of our patients.